Prognostic factors of hepatosplenic T-cell lymphoma clinicopathologic study of 28 cases

Mariko Yabe, L. Jeffrey Medeiros, Guilin Tang, Sa A. Wang, Sairah Ahmed, Yago Nieto, Shimin Hu, Govind Bhagat, Yasuhiro Oki, Keyur P. Patel, Mark Routbort, Rajyalakshmi Luthra, Michelle A. Fanale, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Francisco Vega, Weina Chen, Daniela Hoehn, Sergej Konoplev, Denai R. MiltonIgnacio Wistuba, Shaoying Li, M. James You, Ken H. Young, Roberto N. Miranda

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Hepatosplenic T-cell lymphoma (HSTCL) is a rare type of lymphoma. Patients have a poor prognosis, and there is no standard of care. We evaluated 28 HSTCL patients to determine factors that may be associated with outcome. There were 19 men and 9 women with a median age of 32.5 years. Most patients had massive splenomegaly, and bone marrow showed sinusoidal involvement by lymphoma. The HSTCL cells expressed γδ T-cell receptor (TCR) in 20 (74%), αβ TCR in 5 (19%), and neither in 2 (7%) patients (1 case not assessed). Conventional cytogenetics and/or fluorescence in situ hybridization analysis in 24 patients at diagnosis showed isochromosome 7q (i7q) in 10 (42%) and trisomy 8 in 8 (33%) patients. Median overall survival (OS) and event-free survival (EFS) were each 28.3 months. Serum bilirubin level ≥1.5 mg/dL, ab TCR expression, and trisomy 8 each correlated significantly with shorter OS and EFS. Patients with HSTCL received a variety of chemotherapy regimens with no regimen better than any other. However, patients who underwent stem cell transplant showed longer survival (OS: hazard ratio 0.3, P = 0.09; EFS: hazard ratio 0.2, P = 0.034). In conclusion, although HSTCL patients have a poor prognosis overall, the data presented support the novel suggestions that HSTCL patients can be stratified into 2 prognostic groups, with an elevated serum bilirubin level, αβ TCR expression, and trisomy 8 identifying a poorer prognostic group. In addition, the outcomes of this patient cohort suggest that stem cell transplantation has value for the treatment of patients with HSTCL.

Original languageEnglish (US)
Pages (from-to)676-688
Number of pages13
JournalAmerican Journal of Surgical Pathology
Volume40
Issue number5
DOIs
StatePublished - Jan 1 2016

Keywords

  • Hepatosplenic T-cell lymphoma
  • Prognostic factors
  • Stem cell transplant

ASJC Scopus subject areas

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Prognostic factors of hepatosplenic T-cell lymphoma clinicopathologic study of 28 cases'. Together they form a unique fingerprint.

  • Cite this

    Yabe, M., Medeiros, L. J., Tang, G., Wang, S. A., Ahmed, S., Nieto, Y., Hu, S., Bhagat, G., Oki, Y., Patel, K. P., Routbort, M., Luthra, R., Fanale, M. A., Bueso-Ramos, C. E., Jorgensen, J. L., Vega, F., Chen, W., Hoehn, D., Konoplev, S., ... Miranda, R. N. (2016). Prognostic factors of hepatosplenic T-cell lymphoma clinicopathologic study of 28 cases. American Journal of Surgical Pathology, 40(5), 676-688. https://doi.org/10.1097/PAS.0000000000000614